Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Genotyping of patients treated with selective serotonin reuptake inhibitors.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Transliterated Title:
Genotyping av pasienter behandlet med selektive serotoninreopptakshemmere.
- Source:
Publisher: Norske Laegeforening Country of Publication: Norway NLM ID: 0413423 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 0807-7096 (Electronic) Linking ISSN: 00292001 NLM ISO Abbreviation: Tidsskr Nor Laegeforen Subsets: MEDLINE
- Publication Information:
Publication: Oslo : Norske Laegeforening
Original Publication: Chistiania : Alb. Cammermeyer, 1880-
- Subject Terms:
- Abstract:
Background: Selective serotonin reuptake inhibitors (SSRIs) are used by over 180,000 people in Norway. The enzymes CYP2D6 and CYP2C19 are key in the metabolism of SSRI antidepressants. The serotonin transporter coded by SLC6A4 may be significant for the efficacy of the drugs.
Material and Method: All patients who had undergone genotyping for CYP2D6, CYP2C19 and SLC6A4 at the Centre for Psychopharmacology in 2020 were included, irrespective of indication. For those patients where data were available, CYP2C19 genotype was linked to serum concentration measurement of escitalopram, which is the most commonly used SSRI drug.
Results: Out of 3,492 patients, 432 (12.4 %) had a combination of genotypes of CYP2D6, CYP2C19 and SLC6A4 considered to lead to the most favourable metabolism and efficacy of SSRI antidepressants. The dose requirement in patients with poor CYP2C19 metabolism was more than halved to achieve the same concentration of escitalopram compared to patients with normal metabolism.
Interpretation: Our findings demonstrate the low prevalence of the most favourable genotype combination for response to SSRIs. Genotype combinations probably contribute to the wide variation between individuals in the efficacy of these drugs and the fact that treatment does not produce the desired outcome in many patients.
- Comments:
Comment in: Tidsskr Nor Laegeforen. 2022 Nov 07;142(16):. (PMID: 36345637)
Comment in: Tidsskr Nor Laegeforen. 2022 Nov 21;142(17):. (PMID: 36416655)
Comment in: Tidsskr Nor Laegeforen. 2022 Nov 21;142(17):. (PMID: 36416656)
- Accession Number:
0 (Antidepressive Agents)
0 (SLC6A4 protein, human)
0 (Serotonin Plasma Membrane Transport Proteins)
0 (Serotonin Uptake Inhibitors)
4O4S742ANY (Escitalopram)
EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
- Publication Date:
Date Created: 20220927 Date Completed: 20220928 Latest Revision: 20221207
- Publication Date:
20221213
- Accession Number:
10.4045/tidsskr.22.0017
- Accession Number:
36164782
No Comments.